&lt;p&gt;Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor&lt;/p&gt;

Cheng, Jian-De; Chai, Lixun; Zhao, Zhiping; Hao, Ya; Li, Shuo

doi:10.2147/cmar.s253366

Cited by 21 publications

(28 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of adverse events recorded in both groups was low and similar to those reported in the literature [25,[40][41][42][43][44][45][46]. In this study, the proportion of patients rechecking ECG, thyroid function and urine routine was small.…”

Section: Discussionsupporting

confidence: 86%

Anlotinib Is Active for the Patients Failed From the Prior Antiangiogenic Therapy: Anti-angiogenic Therapy Might Be Cross-line Used

Suo¹,

Sun²,

Fu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective The purpose of this study was to initially investigate whether previous antiangiogenic therapy (bevacizumab and endostar) affect the efficacy of anlotinib in patients with lung cancer (LC). Methods We retrospectively collected the clinical data of LC patients treated with anlotinib. They were divided into two groups, namely group A (anlotinib after failure of previous antiangiogenic drugs and group B (no prior use of antiangiogenic drugs). Use propensity score matching (PSM) to control the confounding factors between the groups.Results A total of 160 patients were included in the analysis. The median OS in group A and group B was 11.8 months vs. 16.1 months (P=0.120), and the median PFS was 3.1 months, 4.7 months, respectively (P=0.009). The ORR of the two groups was 9.6% vs. 10.4% (P=0.874), and the DCR was 71.1 % vs. 80.5% (P=0.165).After PSM (n=46), baseline characteristics were equitably comparable between the two groups. It was found that the median OS of the two groups was 14.6 months vs. 16.2 months (P=0.320), and the median PFS was 3.5 months vs. 4.5 months (P=0.040). The ORR of the two groups were 13.0%, 10.9% (P=0.748), and the DCR were 78.3%, 82.6% (P=0.599), respectively. These results provided further evidence that although PFS of group A was relatively shorter than that of group B, it may not affect patients’ OS.Conclusions Previous antiangiogenesis treatments may affect the PFS of patients who receive anlotinib later, but it might not affect the patient’s ORR and OS.

show abstract

Section: Discussionsupporting

confidence: 86%

Anlotinib Is Active for the Patients Failed From the Prior Antiangiogenic Therapy: Anti-angiogenic Therapy Might Be Cross-line Used

Suo¹,

Sun²,

Fu³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Anlotinib is a multitarget tyrosine kinase inhibitor that was originally designed to inhibit VEGFR2/3, FGFR1-4, PDGFRα/β, c-Kit, and Ret ( 16 ), thereby exerting inhibitory effects on tumor angiogenesis and growth ( 13 ), tumor invasion ( 17 ), lymphangiogenesis and lymphatic metastasis ( 18 ). Anlotinib has been shown to be effective in the treatment of advanced non-small cell lung cancer ( 19 ), small cell lung cancer ( 20 ), esophageal squamous cell carcinoma ( 21 ), metastatic colorectal carcinoma ( 22 ), soft tissue sarcoma ( 23 ). Anlotinib has also demonstrated a sustained antitumor activity in locally advanced or metastatic medullary thyroid carcinoma, with a PFS rate of 85.5% at 48 weeks of treatment ( 24 ).…”

Section: Discussionmentioning

confidence: 99%

“…No SAEs occurred in this patient, most of which could be controlled with medication, and a few of which could disappear spontaneously, with grade 3 AEs including diarrhea, hypertension, and headache. Interestingly, hypertension was considered to be a biomarker for efficacy prediction of anlotinib in advanced NSCLC ( 19 ). Hand-foot syndrome persists and affects the patient's quality of life, and also can be relieved by taking celecoxib and applying urea-vitamin E cream.…”

Section: Discussionmentioning

confidence: 99%

Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAFV600E Mutations

Cheng

Qian

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

We describe a case of recurrent and metastatic radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) treated with anlotinib in this report. The patient was randomized to placebo initially, after disease progressed at C8 (C is the treatment cycle), the patient was referred to the open label therapy of anlotinib, 12 mg p.o. daily with a 2-week on/1-week off regimen. Partial response was achieved at C2 with anlotinib treatment. To date, over 37 months of progression-free survival (PFS) has been achieved. Adverse effects were tolerable and manageable in this patient. Molecular characterization revealed coexistent C228T mutation of TERT promoter and BRAFV600E mutations. Favorable clinical outcome in this patient suggests that anlotinib might provide a novel effective therapeutic option for patients with RAIR-DTC. TERT and BRAFV600E mutations may represent as biomarker for predicting salutary effects of anlotinib.

show abstract

“…In advanced NSCLC, anlotinib is a small molecule multi-target tyrosine kinase inhibition of VEGFR1-3, FGFR1-4, and PDGFRα-β, among others. 18,19 It plays a crucial role as a third or further line of targeted therapy and has shown excellent e cacy in treating NSCLC during clinical trials. Anlotinib has also been associated with various adverse reactions, including hyperlipidemia among other symptoms.…”

Section: Introductionmentioning

confidence: 99%

“…15,17 Some previous studies have demonstrated that some elements such as CD31-labled activated circulating endothelial, levels of KLK5 and L1CAM, post-treatment hyperlipidemia, post-treatment hypertension status and pre-treatment ECOG scores, might be potential biomarkers for effectively predicting anlotinib in NSCLC patients. [19][20][21][22] To date, however, these genetic and cytological factors are expensive and inconvenient to obtain, and none of these evidences have described the potential association between blood lipids before treatment and e cacy of anlotinib in treatment of NSCLC. Therefore, we analyzed differences in basal lipids levels during patient survival as well as the effective ratio, and found that these can be a signi cant predictor to guide future individualized treatment.…”

Section: Introductionmentioning

confidence: 99%

Levels of Pretreatment Blood Lipids are Prognostic Factors in Advanced NSCLC Patients Treated with Anlotinib

Tang

Chen²,

Zhang

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Anlotinib, a small molecule for multi-target tyrosine kinase inhibition, is the third or further line of defense for treatment of non-small cell lung cancer (NSCLC). Results from an ALTER0303 phase III trial revealed that this drug confers significant survival benefits in patients. Although numerous inflammatory biomarkers play a vital role in treatment, none of them has focused on blood lipids before treatment. Here, we explored the relationship between blood lipids and efficacy of anlotinib, with a view of generating insights to guide future development of convenient and individualized treatment therapies. Methods: We analyzed basal blood lipids, including triglyceride (TG), total cholesterol (TC), low density lipoprotein (LDL), and high density lipoprotein (HDL), among other variables before treatment, in 137 patients with advanced NSCLC who received anlotinib as third or further-line treatment at the Ningbo Medical Center Lihuili Hospital, between July 2018 and December 2020. We selected the best cut off value for predicting treatment response, generated survival curves using the Kaplan–Meier method, then applied univariate and multivariate Cox regression analyses to assess predictors of survival. Results: The entire study population recorded median progression-free survival (PFS) and overall survival (OS) of 4 (95% CI 3.142-4.858) and 8.3 (95% CI 6.843-9.757) months, respectively. We observed statistically significant differences across subgroup, between blood lipid indexes with different efficacies, except in the HDL subgroup. The low Disease control rate (DCR) was associated with significantly high TG, high TC and high LDL (P = 0.000). Results from multivariate analysis demonstrated that high TC and high LDL were independently associated with poor PFS or OS (P ≤ 0.003). We used these results to establish a prediction model, and set high TC or high LDL as risk factors, respectively. The outcomes significant difference between 0 and ≥1 scores in PFS (P = 0.000) and OS (P = 0.012).Conclusions: TC and LDL, before anlotinib therapy, were independent prognostic indicators for patients with advanced NSCLC who received this drug as a third or further-line of treatment. In addition, a risk score of 0 was attributed to a combination between low TC and low LDL, and these patients were exhibited excellent efficacy and survival rates.

show abstract

<p>Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor</p>

Cited by 21 publications

References 40 publications

Anlotinib Is Active for the Patients Failed From the Prior Antiangiogenic Therapy: Anti-angiogenic Therapy Might Be Cross-line Used

Anlotinib Is Active for the Patients Failed From the Prior Antiangiogenic Therapy: Anti-angiogenic Therapy Might Be Cross-line Used

Case Report: Anlotinib Therapy in a Patient With Recurrent and Metastatic RAIR-DTC Harboring Coexistent TERT Promoter and BRAFV600E Mutations

Levels of Pretreatment Blood Lipids are Prognostic Factors in Advanced NSCLC Patients Treated with Anlotinib

Contact Info

Product

Resources

About